| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
WX2-43 (biotin-labeled WX2-43; 0.1 nM–10 μM; 2 h) binds to PRMT5 with a Kd value of 11.0 nM [1]. WX2-43 (0.03–10 μM; 24 h) inhibits the viability of cisplatin-treated MEF cells in a KLF4-dependent manner [1]. The potency of WX2-43 in triple-negative breast cancer (TNBC) cell lines (EC50 0.44–0.96 μM) is higher than that in normal breast epithelial cell lines (EC50 3.62–23.34 μM) [1]. WX2-43 induces a mesenchymal-like phenotype in two-dimensional (2D) AKPS cultures, alters colony morphology, size, and actin cytoskeleton, and reduces the frequency of Ki-67+ cells [2].
|
|---|---|
| ln Vivo |
WX2-43 (40-80 mg/kg; intraperitoneal injection; twice a week; 4 weeks) inhibited the progression of triple-negative mammary tumors in nude mice [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: KLF4+/+ MEFs, KLF4-/- MEFs Tested Concentrations: 0, 0.03, 0.1, 0.3, 1, 3, 10 μM (WX2-43); 5 μM (cisplatin) Incubation Duration: 24 hours Experimental Results: The viability of KLF4+/+ MEFs decreased in a dose-dependent manner; it had no effect on the viability of KLF4-/- MEFs. Western Blot Analysis [1] Cell Types: MDA-MB-231 Tested Concentrations: 0, 0.1, 1, 10 μM Incubation Duration: 24 hours Experimental Results: KLF4 and p21 protein levels decreased in a dose-dependent manner, while Bax levels increased in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models:Crl: Nu-Foxn1(nu) (female, 8 weeks old)[1]
Doses: 40 mg/kg; 80 mg/kg Route of Administration: Intraperitoneal injection; twice a week; 4 weeks Experimental Results: Compared with the carrier, the tumor volume and weight of the 40 mg/kg dose group were reduced by about 40%; compared with the carrier, the tumor volume and weight of the 80 mg/kg dose group were reduced by about 60%; the decrease in KLF4 protein level in the treatment group was confirmed by Western blotting. |
| References |
| Molecular Formula |
C17H21CLN2
|
|---|---|
| Molecular Weight |
288.82
|
| CAS # |
723754-14-1
|
| Appearance |
White to off-white solid
|
| SMILES |
ClC1=CC=C(C=C1)NCC2=CC=C(C=C2)N(CC)CC
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~346.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4624 mL | 17.3118 mL | 34.6236 mL | |
| 5 mM | 0.6925 mL | 3.4624 mL | 6.9247 mL | |
| 10 mM | 0.3462 mL | 1.7312 mL | 3.4624 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
